NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
NeOnc Technologies (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, November 12, 2025 at 6:00 a.m. PT / 9:00 a.m. ET (prior to market open).
Management and independent Scientific Advisory Board members will present data updates from the ongoing Phase 1/2a NEO100-1 trial and compassionate use program, covering intranasal NEO100 (high-purity perillyl alcohol) in recurrent high-grade malignant glioma patients. Presentations will highlight MRI-based radiographic responses, progression-free survival (PFS), and overall survival (OS) trends observed to date. The live webcast will be available at https://investors.neonc.com.
NeOnc Technologies (Nasdaq: NTHI) ospiterà una conference call per investitori e una trasmissione webcast mercoledì 12 novembre 2025 alle 6:00 (PT) / 9:00 (ET) (prima dell'apertura dei mercati).
Il management e i membri del Technical Scientific Advisory Board indipendente presenteranno aggiornamenti sui dati della attuale fase 1/2a NEO100-1 trial e del programma di uso compassionevole, che riguarda NEO100 intranasale (alcool perillylico di alta purezza) in pazienti con gliomi malingi ad alto grado ricorrenti. Le presentazioni evidenzieranno risposte radiografiche basate su MRI, sopravvivenza senza progressione (PFS) e sopravvivenza globale (OS) osservate fino ad ora. La webcast in diretta sarà disponibile su https://investors.neonc.com.
NeOnc Technologies (Nasdaq: NTHI) organizará una conferencia telefónica para inversores y una transmisión web el miércoles 12 de noviembre de 2025 a las 6:00 a.m. PT / 9:00 a.m. ET (antes de la apertura del mercado).
Los miembros de la dirección y del Consejo Científico Independiente presentarán actualizaciones de datos de la actual fase 1/2a NEO100-1 ensayo y programa de uso compasivo, que cubre NEO100 intranasal (alcohol de perillyl de alta pureza) en pacientes con glioma maligno de alto grado recurrente. Las presentaciones destacarán respuestas radiográficas basadas en RM, supervivencia libre de progresión (PFS), y supervivencia global (OS) observadas hasta la fecha. La transmisión en vivo estará disponible en https://investors.neonc.com.
NeOnc Technologies (Nasdaq: NTHI) 투자자 컨퍼런스 콜 및 웹캐스트를 2025년 11월 12일 수요일 오전 6:00 PT / 오전 9:00 ET에 개최합니다(시장 개장 전에).
경영진과 독립 과학 자문 위원회 위원들은 진행 중인 1상/2상 NEO100-1 임상 연구 및 연민적 사용 프로그램의 데이터 업데이트를 제시하고, 고형 악성 교모세포종 재발 환자에서의 비강 내 NEO100(고순도 페릴릴 알코올)을 다룰 예정입니다. 발표에서는 MRI 기반 방사선 반응, 무진행 생존기간(PFS) 및 전반적 생존(OS) 추세가 지금까지 관찰된 바를 강조합니다. 생방송 웹캐스트는 https://investors.neonc.com에서 시청 가능.
NeOnc Technologies (Nasdaq: NTHI) organisera une conférence téléphonique et une diffusion Web pour les investisseurs le mercredi 12 novembre 2025 à 6h00 PT / 9h00 ET (avant l’ouverture des marchés).
La direction et les membres du conseil consultatif scientifique indépendant présenteront des mises à jour des données de l’essai de phase 1/2a NEO100-1 en cours et du programme d’utilisation compassionnelle, couvrant NEO100 intranasal (alcool de périllyle de haute pureté) chez les patients atteints de gliome malin de haut grade récurrent. Les présentations mettront en évidence réponses radiographiques basées sur l’IRM, survie sans progression (PFS) et survie globale (OS) observées à ce jour. Le webcast en direct sera disponible à https://investors.neonc.com.
NeOnc Technologies (Nasdaq: NTHI) wird am Mittwoch, dem 12. November 2025 um 6:00 Uhr PT / 9:00 Uhr ET eine Investorenkonferenzschaltung und einen Webcast ausrichten (vor Börsenöffnung).
Management und unabhängige Mitglieder des Scientific Advisory Board werden Datenaktualisierungen aus der laufenden Phase-1/2a NEO100-1 Studie und dem Compassionate-Use-Programm präsentieren, einschließlich intranasalem NEO100 (hochreines Perillylalkohol) bei rezidivierenden Hochgrad-Gliomen. Die Präsentationen heben MRI-basierte radiologische Reaktionen, krankheitsfreies Überleben (PFS) und gesamtüberleben (OS) bis heute hervor. Der Live-Webcast ist verfügbar unter https://investors.neonc.com.
NeOnc Technologies (Nasdaq: NTHI) ستستضيف مكالمة مؤتمر للمستثمرين وبثًا حيًا عبر الويب يوم الأربعاء 12 نوفمبر 2025 في الساعة 6:00 صباحًا بتوقيت المحيط الهادئ / 9:00 صباحًا بتوقيت شرق الولايات المتحدة (قبل فتح السوق).
سيقدّم المدراء وأعضاء مجلس المستشارين العلمي المستقلون تحديثات البيانات من تجربة المرحلة 1/2a NEO100-1 الجارية وبرنامج الاستخدام العلاجي بالرحمة، التي تغطي NEO100 داخل الأنف (الكحول البرليلي عالي النقاء) لدى مرضى الورم الدبقي عالي الدرجة المتكرر. ستُبرز العروض استجابات تصويرية قائمة على MRI، البقاء الحر من التقدم (PFS) و النجاة الإجمالية (OS) حتى تاريخه. ستكون البثوث المباشرة متاحة على https://investors.neonc.com.
- None.
- None.
Insights
NeOnc will present interim clinical and compassionate‑use data for intranasal NEO100 on
The presentation focuses on MRI radiographic responses, progression‑free survival (PFS) and overall survival (OS) trends from the ongoing Phase 1/2a NEO100‑1 trial and compassionate use cases. These endpoints are standard clinical measures for recurrent high‑grade malignant glioma and can materially affect clinical development decisions if the data show meaningful signal versus expected natural history.
Key dependencies and risks include the absence here of numeric results, formal statistical analyses, or declared primary endpoint achievement; therefore the announcement merely schedules disclosure rather than reporting outcomes. Watch the live webcast on
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open).
During the call, members of the NTHI management team and independent members of the company’s Scientific Advisory Board (SAB) will present data updates from the Company’s ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program, evaluating intranasal delivery of NEO100 (high-purity perillyl alcohol) in patients with recurrent high grade malignant glioma.
The discussion will highlight MRI-based radiographic response data, progression-free survival (PFS), and overall survival (OS) trends observed to date, providing important insights into long-term clinical outcomes for patients treated with NEO100.
Featured Participants:
- Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University; Independent Member, NTHI Scientific Advisory Board
- Dr. Alexander Miller, MD – Chief Neuro-oncology, Brain Tumor Program, NYU Langone Health; Independent Member, NTHI Scientific Advisory Board
- NTHI Management Team:
- Amir Heshmatpour – Chief Executive Officer, Executive Chairman and President
- Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer and Chief Scientific Officer
- Dr. Josh Neman, PhD – Chief Clinical Officer
- Keith Garnett – Chief Financial Officer
Conference Call Details:
- Date: Wednesday, November 12, 2025
- Time: 6:00 a.m. PT / 9:00 a.m. ET
- Webcast: A live webcast can be accessed by visiting https://investors.neonc.com
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
When is the NeOnc (NTHI) investor conference call to present NEO100-1 data?
What clinical data will NeOnc (NTHI) present on the November 12, 2025 call?
How can investors access the NeOnc (NTHI) November 12, 2025 webcast?
Which NeOnc (NTHI) speakers will present NEO100 clinical updates on November 12, 2025?
What is the investigational therapy discussed by NeOnc (NTHI) on the November 12, 2025 call?
